Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.5% – Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares were down 4.5% during trading on Wednesday . The company traded as low as $11.53 and last traded at $11.54. Approximately 45,000 shares were traded during trading, a decline of 35% from the average daily volume of 68,897 shares. The stock had previously closed at $12.09.

Gyre Therapeutics Trading Down 3.7 %

The stock has a 50 day moving average of $13.67 and a 200-day moving average of $12.86.

Institutional Trading of Gyre Therapeutics

A number of large investors have recently made changes to their positions in GYRE. Bank of New York Mellon Corp purchased a new position in shares of Gyre Therapeutics during the second quarter valued at $218,000. Rhumbline Advisers bought a new stake in Gyre Therapeutics during the second quarter valued at about $123,000. WINTON GROUP Ltd acquired a new stake in Gyre Therapeutics in the second quarter worth about $220,000. Renaissance Technologies LLC acquired a new stake in Gyre Therapeutics in the second quarter worth about $166,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after acquiring an additional 90,557 shares in the last quarter. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.